青光眼是全球第二大失明原因,影响超过6400万40-80岁的人。治疗原发性开角型青光眼(POAG)的最佳方法是降低眼内压(IOP)。Netarsudil是一种Rho激酶抑制剂,唯一一类重组细胞外基质以改善通过小梁途径的房水流出的抗青光眼药物。
■开放标签,真实世界,多中心,我们进行了为期3个月的观察研究,以评估netarsudil眼用溶液(0.02%w/v)在IOP升高患者中的安全性和降低眼压的疗效.患者接受netarsudil眼用溶液(0.02%w/v)作为一线治疗。昼夜眼压测量,最佳矫正视力,和不良事件评估在五次访问中的每一次记录(第1天:筛选日和第一次给药日;随后的观察在2周进行,4周,6周,和3个月)。
■来自印度39个中心的四百六十九名患者完成了这项研究。受影响眼睛基线时的平均IOP为24.84±6.39mmHg(平均值±标准偏差)。第一次给药之后,在2、4和6周后测量IOP,在3个月时进行最终测量。每天一次的netarsudil0.02%w/v溶液使用3个月后,青光眼患者的眼压降低百分比为33.34%。在大多数情况下,患者经历的不良反应并不严重。观察到的一些不良反应是发红,刺激,瘙痒,和其他人,但是只有少数患者出现了严重的反应,按降序报告:发红>刺激>浇水>瘙痒>刺痛>模糊。
■我们发现netarsudil0.02%w/v溶液单药治疗原发性开角型青光眼和高眼压症的一线治疗既安全又有效。
UNASSIGNED: Glaucoma is the second leading cause of blindness worldwide, affecting more than 64 million people aged 40-80. The best way to manage primary open-angle glaucoma (POAG) is by lowering the intraocular pressure (IOP). Netarsudil is a Rho kinase inhibitor, the only class of antiglaucoma medications that reorganizes the extracellular matrix to improve the aqueous outflow through the trabecular pathway.
UNASSIGNED: An open-label, real-world, multicentric, observation-based 3-month study was performed for assessing the safety and ocular hypotensive efficacy of netarsudil ophthalmic solution (0.02% w/v) in patients with elevated IOP. Patients were given netarsudil ophthalmic solution (0.02% w/v) as a first-line therapy. Diurnal IOP measurements, best-corrected visual acuity, and adverse event assessments were recorded at each of the five visits (Day-1: screening day and first dosing day; subsequent observations were taken at 2 weeks, 4 weeks, 6 weeks, and 3 months).
UNASSIGNED: Four hundred and sixty-nine patients from 39 centers throughout India completed the study. The mean IOP at baseline of the affected eyes was 24.84 ± 6.39 mmHg (mean ± standard deviation). After the first dose, the IOP was measured after 2, 4, and 6 weeks, with the final measurement taken at 3 months. The percentage reduction in IOP in glaucoma patients after 3 months of once-daily netarsudil 0.02% w/v solution use was 33.34%. The adverse effects experienced by patients were not severe in the majority of cases. Some adverse effects observed were redness, irritation, itching, and others, but only a small number of patients experienced severe reactions, as reported in a decreasing order: redness > irritation > watering > itching > stinging > blurring.
UNASSIGNED: We found that netarsudil 0.02% w/v solution monotherapy when used as the first-line treatment in primary open-angle glaucoma and ocular hypertension was both safe and effective.